Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Momenta Pharmaceuticals has filed lawsuit against Teva Pharmaceutical Industries in the US District Court for the District of Massachusetts for infringement of two Momenta Pharma patents.
Subscribe to our email newsletter
The patents cover the Momenta Pharma’s methods of producing Enoxaparin sodium, which assure that the commercial product meets standards for identity and quality.
One patent, US Patent no. 7,790,466, is related to methods of processing Enoxaparin to determine the presence of certain tetrasaccharide structures.
However, the second patent, US Patent no. 7,575,886, is related to methods of analysing Enoxaparin for the presence of a certain structural signature.
Teva said that its generic version of Lovenox, which is manufactured and tested outside of the US, does not infringe either of these patents.
Teva believes that this lawsuit is without merit, and Teva intends to seek reimbursement for all legal fees in fighting these baseless allegations.
Momenta president and CEO Craig Wheeler said that Momenta has made a substantial investment in the development of novel methods that make it possible to assure the quality of complex products.